See more : Infinite Technology Corporation (ITCJ) Income Statement Analysis – Financial Results
Complete financial analysis of Enliven Therapeutics, Inc. (ELVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enliven Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- American Oncology Network, Inc. (AONC) Income Statement Analysis – Financial Results
- Graphene Manufacturing Group Ltd (GMGMF) Income Statement Analysis – Financial Results
- Headwater Exploration Inc. (CDDRF) Income Statement Analysis – Financial Results
- Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) Income Statement Analysis – Financial Results
- Liaoning Shenhua Holdings Co.,Ltd (600653.SS) Income Statement Analysis – Financial Results
Enliven Therapeutics, Inc. (ELVN)
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 297.00K | 622.00K | 99.00K | 97.00K | 33.00K | 0.00 | 0.00 |
| Gross Profit | -297.00K | -622.00K | -99.00K | -97.00K | -33.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 64.57M | 31.02M | 20.47M | 8.24M | 19.01M | 8.24M | 7.92M |
| General & Administrative | 18.96M | 7.77M | 4.29M | 1.08M | 5.11M | 2.44M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -33.00K | 0.00 | 0.00 |
| SG&A | 18.96M | 7.77M | 4.29M | 1.08M | 5.07M | 2.44M | 987.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.68M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.08M | 10.68M | 8.91M |
| Cost & Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.12M | 10.68M | 8.91M |
| Interest Income | 11.97M | 1.13M | 22.00K | 31.00K | 578.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 297.00K | 215.00K | 115.00K | 97.00K | 33.00K | -660.00K | 0.00 |
| EBITDA | -81.93M | -38.58M | -24.65M | -9.27M | -23.43M | -11.34M | 221.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.53M | -38.79M | -24.76M | -9.32M | -24.12M | -10.68M | -8.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.95M | 1.13M | 22.00K | -9.65M | 653.00K | -660.00K | 9.13M |
| Income Before Tax | -71.58M | -37.66M | -24.74M | -18.97M | -23.46M | -11.34M | 221.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 88.00K | -22.00K | -31.00K | 653.00K | -821.14K | 221.00K |
| Net Income | -71.58M | -37.75M | -24.72M | -18.94M | -23.46M | -11.34M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| EPS Diluted | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| Weighted Avg Shares Out | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
| Weighted Avg Shares Out (Dil) | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following...
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?
3 Best Penny Stocks To Buy Before November According To Insiders
Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
New to Trading Penny Stocks? Must Knows in 2022
Are these methods part of your penny stocks trading strategy The post New to Trading Penny Stocks? Must Knows in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Imara (IMRA) Stock Soars 35% on Merger Agreement
Imara (NASDAQ: IMRA ) stock is rocketing higher on Friday after the company revealed plans for a merger agreement with Enliven Therapeutics. The merger agreement will involve no cash and instead see the two companies use stock to fuel the...
Imara: Potential Liquidation
Imara has announced strategic alternatives and has announced the sale its key asset. It now trades 37% below its Pro Forma net cash levels and a liquidation would be ideal.
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?
Here is how IMARA Inc. (IMRA) and Viracta (VIRX) have performed compared to their sector so far this year.
3 High Volume Penny Stocks To Watch Before Next Week
Here's what you need to know about buying penny stocks on September 9th, 2022 The post 3 High Volume Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports